Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aegis Capital Keeps Amarin (AMRN) at 'Hold'; Cautious on Vascepa for Dyslipidemia Strategy
February 28, 2014 9:22 AM ESTAegis Capital reaffirms its Hold rating and $2 price target on Amarin Coop plc (Nasdaq: AMRN) on Friday following Q4 results and update.
Analyst Ram Selvaraju commented, We believe that Amarin can achieve management's stated financial goals, even with a significantly reduced revenue base for Vascepa in hypertriglyceridemia only. However, we remain... More
Amarin Corp Plc (AMRN) Posts Q4 Loss of 26c/Share; Update on Ops
February 27, 2014 4:03 PM ESTAmarin Corp Plc (NASDAQ: AMRN) reported Q4 EPS of ($0.26), $0.03 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $11.17 million.
Key Amarin milestones since September 30, 2013 include:
-- Recognized $26.4 million in product revenue from Vascepa® sales in 2013, the first year of Vascepa sales, including revenue growth to... More
